Siste måned

30 dager
+128 595
NETTO POSISJON (NOK)
Handler
6
Kjøp
128 595
Salg
0

6 måneder

180 dager
+586 730
NETTO POSISJON (NOK)
Handler
26
Kjøp
586 730
Salg
0

Historikk

ℹ️ Om innsidehandel

Primærinnsidere er personer med ledelsesansvar og deres nærstående. Meldeplikt inntrer når transaksjoner når EUR 5 000 i et kalenderår.

Meldefrist: umiddelbart, senest tre virkedager. Handelsforbud 30 dager før pliktig finansiell rapportering.

Transaksjoner

Dato Innsider Antall Pris Verdi
30.01.2026
Damian Marron
Chairman
128 595 1.00 128 595
13.02.2026
Ola Melin
Chief Operation Officer
500 000 - -
13.02.2026
Thomas Birkballe Hansen
Chief Technology Officer
750 000 - -
13.02.2026
Victor Levitsky
Chief Scientific Officer
500 000 - -
13.02.2026
Lubor Gaal
CFO
750 000 - -
13.02.2026
Erik Digman Wiklund
CEO
1 200 000 - -
28.01.2026
Lubor Gaal
CFO
via Biopharma Drug Licensing Group, SL
65 164 1.00 65 164
27.01.2026
Thomas Falck
Board member
via Sølen AS
65 164 1.00 65 164
26.01.2026
Victor Levitsky
Chief Scientific Officer
32 698 1.00 32 698
21.01.2026
Ola Melin
Chief Operation Officer
33 161 1.00 33 161
21.01.2026
Damian Marron
Chairman
58 918 1.00 58 918
21.01.2026
Robert Forbes Burns
Deputy Board member
11 542 1.00 11 542
21.01.2026
Diane Mary Mellet
Board member
60 000 1.00 60 000
19.01.2026
Thomas Birkballe Hansen
Chief Technology Officer
32 582 1.00 32 582
16.01.2026
Erik Digman Wiklund
CEO
97 746 1.00 97 746
16.01.2026
Erik Digman Wiklund
CEO
via Digman AS
1 160 1.00 1 160
15.01.2026
Robert Forbes Burns
Deputy Board member
30 792 - -
15.01.2026
Diane Mary Mellet
Board member
67 405 - -
15.01.2026
Thomas Falck
Board member
via Sølen AS
65 164 - -
15.01.2026
Victor Levitsky
Chief Scientific Officer
32 698 - -
15.01.2026
Lubor Gaal
CFO
via Biopharma Drug Licensing Group, SL
65 164 - -
15.01.2026
Thomas Birkballe Hansen
Chief Technology Officer
32 582 - -
15.01.2026
Ola Melin
Chief Operation Officer
33 162 - -
15.01.2026
Erik Digman Wiklund
CEO
97 746 - -
15.01.2026
Erik Digman Wiklund
CEO
via Digman AS
1 160 - -
15.01.2026
Damian Marron
Chairman
58 918 - -
Vis alle 26 transaksjoner

Pressemeldinger

Dato Melding
26.02.2026
Correction - Mandatory notification of trade by primary insider related to the rights issue
NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, ...
14.02.2026
Circio announces allocation of stock options to key employees
Oslo, Norway, 14 February 2026 -- Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene...
29.01.2026
Circio Holding ASA Exercise of subscription rights in the rights issue by primary insiders
Oslo, 29 January 2026: Reference is made to the stock exchange announcements by Circio Holding ASA (the "Company") on 15 January 2026, regarding the c...
28.01.2026
Circio Holding ASA Exercise of subscription rights in the rights issue by primary insiders
Oslo, 28 January 2026: Reference is made to the stock exchange announcements by Circio Holding ASA (the "Company") on 15 January 2026, regarding the c...
21.01.2026
Circio Holding ASA Exercise of subscription rights in the rights issue by primary insiders
Oslo, 21 January 2026: Reference is made to the stock exchange announcements by Circio Holding ASA (the "Company") on 15 January 2026, regarding the c...
16.01.2026
Circio Holding ASA Exercise of subscription rights in the rights issue by primary insiders
Oslo, 16 January 2026: Reference is made to the stock exchange announcements by Circio Holding ASA (the "Company") on 15 January 2026, regarding the c...
15.01.2026
Circio Holding ASA Receipt of subscription rights in the rights issue by primary insiders and their close associates
Oslo, 15 January 2026: Reference is made to the stock exchange announcement by Circio Holding ASA (the "Company") earlier today, 15 January 2026, rega...
Vis alle 7 meldinger